S
ED, Portfolio Strategy and Strategic Planning, Global Human Health, Merck
MOST RECENT HIT: Global marketing of diabetes blockbuster Januvia
ROLE MODELS: William F. Buckley, Jr. ("strategic thinking, conservative, firm, a change agent")
Blair Gibson
Blair Gibson always wanted a career in pharma. He studied medicinal chemistry, and had his heart set on research until his mentor gave him a reality check. "He said, 'You'd be a disaster in the lab, but you have a very outgoing personality. Your route should be on the commercial side." Harsh—but good advice. Starting out in the field, Gibson gained a place on the team that brought first-in-class diabetes drug Januvia to market—widely viewed as one of the fastest, most successful launches in pharma history. His reward? A promotion in January to a newly created position that Gibson translates as optimizing Merck's promotional spend across all marketed and pipeline products, and all geographies. "Strategy around resource allocation and portfolio management is needed now more than ever," Gibson says. "And while the discipline is flying below the radar, when the work starts coming out in June or July, it will be a new process, a new framework, a new way of looking at our promotional spend"—estimated to be as high as $8 billion. That's a lot of chips to gamble with. For Gibson, it allows him to keep his eye on the big picture while giving his outgoing personality a chance to make a big impact.
FDA Approves Roche’s Susvimo Refillable Eye Implant for Diabetic Macular Edema
February 4th 2025Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing sustained vision improvements with fewer treatments than standard eye injections.
The Future of Fertility: AI, Personalized Medicine, and Ethical Considerations
January 30th 2025Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses how to combat the spread of misinformation on social media, opportunities that social media presents, advancements in fertility technology, and more.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.